SCHEMBL2480282

SCHEMBL2480282

NC(=O)c1cnc(Cl)cc1NCc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 6/20 0.67
IRAK4 Q9NWZ3 4/20 0.67
JAK2 O60674 2/20 0.67
JAK1 P23458 2/20 0.67
TYK2 P29597 2/20 0.67
CDC7 O00311 1/20 0.54
ROCK2 O75116 1/20 0.54
MAP4K4 O95819 1/20 0.54
GSK3B P49841 1/20 0.54
CLK4 Q9HAZ1 1/20 0.54
MKNK2 Q9HBH9 1/20 0.54
KDM4E B2RXH2 2/20 0.52
ASPH Q12797 1/20 0.52
RIOX2 Q8IUF8 1/20 0.52
KDM8 Q8N371 1/20 0.52
RPS6KB1 P23443 2/20 0.52
AKT1 P31749 1/20 0.52
STAT6 P42226 2/20 0.51
CSF1R P07333 1/20 0.50
BTK Q06187 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4409419 0.90 KDM4E (0.60) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2479527 0.89 JAK3 (0.53) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2713876 0.88 RPS6KB1 (0.55) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2482471 0.88 RPS6KB1 (0.60) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL12280211 0.88 CDC7 (0.53) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL12456545 0.88 JAK3 (0.52) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL913752 0.87 CDK5 (0.62) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL12456033 0.87 RPS6KB1 (0.54) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2482122 0.86 RPS6KB1 (0.52) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2479053 0.86 KDM4E (0.51) JAK3IRAK4JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2975027-A1 NICOTINAMIDES AS JAK KINASE MODULATORS Portola Pharmaceuticals, Inc. (US) 2016-01-20 EP disclosed
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 US disclosed
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 US disclosed
US-9102625-B2 Nicotinamides as JAK kinase modulators PORTOLA PHARMACEUTICALS, INC. (US) 2015-08-11 US disclosed
US-9102625-B2 Nicotinamides as JAK kinase modulators PORTOLA PHARMACEUTICALS, INC. (US) 2015-08-11 US disclosed
CN-102227409-B Pyridine-3-carboxyamide derivative KOWA CO 2014-03-26 CN disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
WO-2012061428-A2 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-10 WO disclosed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
CN-102227409-A Pyridine-3-carboxyamide derivative KOWA CO 2011-10-26 CN disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK JAK3 4/4885IRAK4 37/4885JAK2 1/4885
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK JAK3 4/4885IRAK4 37/4885JAK2 1/4885
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA JAK3 1/4885IRAK4 128/4885JAK2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.